Zhitong Finance App News, Shiyao Group (01093) announced that the phase I/II clinical trial (SYS6088-001) of SYS6088 injection (this product) developed by the Group for the treatment of advanced solid tumors () has been officially launched at the first research center in China.

This product is a recombinant humanized anti-programmed death receptor 1 (PD1), vascular endothelial growth factor A (VEGFA), and cytotoxic T-lymphocyte-related antigen 4 (CTLA4). It can specifically bind PD1, CTLA4 on the surface of target cell membranes and VEGFA in the tumor microenvironment to restore the killing function of T lymphocytes (T cells) in the tumor microenvironment, inhibit angiogenesis, and amplify T cells during the immune activation phase. The modification of the Fc terminal reduces the risk of toxicity of this product and can effectively extend its half-life.

The Group received the “Drug Clinical Trial Approval Notice” issued by the China National Drug Administration in October 2026, and commenced phase I clinical trials of this product after approval. The phase I/II clinical trial initiated this time is the first human study to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics and initial anti-tumor efficacy of this product in patients with advanced solid tumors. Currently, the recruitment and screening of participants for this clinical trial is being actively promoted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.